Kintara Therapeutics Inc. (NASDAQ: KTRA) stock gains by 18.58% in the current market trading. Kintara, based in San Diego, California, is focused on the development of novel cancer treatment for patients who have medical needs that are currently unmet. Kintara is working on two late-stage, Phase 3-ready therapeutics with low-risk development programs for clear unmet medical needs. GBM is treated with VAL-083, while cutaneous metastatic breast cancer is treated with REM-001 (CMBC).
What is happening?
The VAL-083 treatment arm in the Global Partnership for Adaptive Research (GCAR) registrational Phase 2/3 clinical study for glioblastoma multiforme (GBM) has been initiated in 15 U.S. sites as of May 14, 2021, according to Kintara Therapeutics.
GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is a patient-centered, evolutionary platform trial for registration assessing multiple therapies for recently diagnosed and recurrent GBM patients. With growing awareness of Kintara’s arm of study in the medical world, GCAR has increased the process of clinical site stimulation since January 2021. In the Kintara arm of the study, GCAR intends to enlist 150-200 patients at 30 sites across the United States and Canada, with the possibility of expanding to 40 clinical trial centers.
Saiid Zarrabian, Kintara’s Chief Executive Officer stated:
The rapid activation of their treatment arm in the study has enthralled the whole Kintara team. KTRA is thrilled to experience GCAR’s outstanding clinical trial results which drew them to take part in this thrilling and super effective registrational with 15 sites already active, including prestigious centers such as Memorial Sloan Kettering, Henry Ford Cancer Institute, Columbia University Irving Cancer Research Center, Emory University Winship Cancer Institute, and the University of Florida.